Sangamo Therapeutics, Inc. SGMO Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sangamo Therapeutics, Inc. SGMO

SGMO 0.460

0.0%

Nov 28 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: bob zagorin	6/20/2007 3:07:56 AM
	Read Replies (1) of 368

from IV site: From C A today - "Looking to buy ahead of ADA on Friday; watch for DN data to shine" Sangamo BioSciences (SGMO : NASDAQ : US$8.19) - Buy - Target US$13.10 Comment: Looking to buy ahead of ADA on Friday; watch for DN data to shine This Friday afternoon (June 22), Sangamo will present updated Phase 1b diabetic neuropathy (DN) data at the American Diabetes Association conference (ADA) in Chicago. Data presented in a podium presentation will include six-month follow-up from a number of placebo-controlled patients as well as follow-up data from the original three patients from the study, which originally showed positive results. There is no change to our investment case for Sangamo, however, we feel it important to highlight the true impact of the upcoming presentation at ADA. We believe that data to date, which has fueled the two ongoing Phase 2 studies in DN, represent critical proof of concept data in humans in being able to restore certain levels of nerve function in "blocked nerve" DN patients. We expect the six-month data to show positive lasting effects from only a single dose. Friday's data should add significant credence to Sangamo's approach, in our belief, and we project price strength at the opening of trading on Monday, June 25. We recommend owning a position in SGMO ahead of Friday afternoon's data release at ADA. We use our probability-weighted NPV model, basing it on the diabetic neuropathy and peripheral artery disease programs, yielding our $13.10 price target. With the potential for both clinical development and business development news flow in the next 12 months, we believe Sangamo's shares warrant a higher valuation.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next